Tumor marker usage and medical care costs among older early-stage breast cancer survivors

Journal of Clinical Oncology

Volumn 33, Issue 2, 2015, Pages 149-155

  Ramsey, Scott D ^a,b   Henry, N Lynn ^c   Gralow, Julie R ^a   Mirick, Dana K ^a   Barlow, William ^a,b   Etzioni, Ruth ^a   Mummy, David ^a   Thariani, Rahber ^b   Veenstra, David L ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CONTROLLED STUDY; DRUG COST; EARLY CANCER; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; AGE; BLOOD; BREAST TUMOR; CANCER REGISTRY; CANCER STAGING; COMORBIDITY; ECONOMICS; FACTORIAL ANALYSIS; HEALTH SURVEY; MEDICARE; PATHOLOGY; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVOR; UNITED STATES; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMORBIDITY; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEALTH CARE COSTS; HUMANS; LOGISTIC MODELS; MEDICARE; NEOPLASM STAGING; POPULATION SURVEILLANCE; RISK FACTORS; SEER PROGRAM; SURVIVORS; UNITED STATES;

EID: 84920920021     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.5409     Document Type: Article

References (23)

1. Molina R, Jo J, Filella X, et al: C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 19:2551-2555, 1999.
2. Molina R, Jo J, Filella X, et al: c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: Prognostic value. Breast Cancer Res Treat 51:109-119, 1998.
3. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007.
4. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001.
5. Rosselli Del Turco M, Palli D, Cariddi A, et al: Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial-National Research Council Project on Breast Cancer followup. JAMA 271:1593-1597, 1994.
6. Palli D, Russo A, Saieva C, et al: Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial- National Research Council Project on Breast Cancer Follow-up. JAMA 281:1586, 1999.
7. Liberati A: The GIVIO trial on the impact of follow-up care on survival and quality of life in breast cancer patients: Interdisciplinary Group for Cancer Care Evaluation. Ann Oncol 6:41-46, 1995.
8. [No authors listed]: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial-The GIVIO Investigators. JAMA 271:1587-1592, 1994.
9. Joseph E, Hyacinthe M, Lyman GH, et al: Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol 5:522-528, 1998.
10. Keating NL, Landrum MB, Guadagnoli E, et al: Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol 25:1074-1081, 2007.
11. Foster JA, Abdolrasulnia M, Doroodchi H, et al: Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer. J Natl Compr Canc Netw 7:697-706, 2009.
12. Hahn EE, Hays RD, Kahn KL, et al: Use of imaging and biomarker tests for postreatment care of early-stage breast cancer survivors. Cancer 119: 4316-4324, 2013.
13. Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715- 1724, 2012.
14. Chan DW, Beveridge RA, Muss H, et al: Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15:2322- 2328, 1997.
15. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000.
16. Chubak J, Yu O, Pocobelli G, et al: Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst 104:931-940, 2012.
17. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 40:373-383, 1987.
18. Oehlert GW: A note on the delta method. Am Statistician 46:27-29, 1992.
19. Han PK, Klabunde CN, Noone AM, et al: Physicians' beliefs about breast cancer surveillance testing are consistent with test overuse. Med Care 51:315-323, 2013.
20. Hensley ML, Dowell J, Herndon JE 2nd, et al: Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat 91: 153-161, 2005.
21. Quek RG, Master VA, Ward KC, et al: Determinants of the combined use of external beam radiotherapy and brachytherapy for low-risk, clinically localized prostate cancer. Cancer 119:3619- 3628, 2013.
22. Hershman DL, Buono D, McBride RB, et al: Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer 115:3848- 3857, 2009.
23. Mandelblatt JS, Berg CD, Meropol NJ, et al: Measuring and predicting surgeons' practice styles for breast cancer treatment in older women. Med Care 39:228-242, 2001.